| Nrf2–ARE pathway: an emerging target against oxidative stress and neuroinflammation in neurodegenerative diseases I Buendia, P Michalska, E Navarro, I Gameiro, J Egea, R Leon Pharmacology & therapeutics 157, 84-104, 2016 | 567 | 2016 |
| The antioxidant additive approach for Alzheimer’s disease therapy: new ferulic (lipoic) acid plus melatonin modified tacrines as cholinesterases inhibitors, direct antioxidants … M Benchekroun, A Romero, J Egea, R León, P Michalska, I Buendía, ... Journal of medicinal chemistry 59 (21), 9967-9973, 2016 | 101 | 2016 |
| The angiotensin‐(1‐7)/Mas receptor axis protects from endothelial cell senescence via klotho and Nrf2 activation A Romero, Á San Hipólito‐Luengo, LA Villalobos, S Vallejo, I Valencia, ... Aging Cell 18 (3), e12913, 2019 | 92 | 2019 |
| Discovery of the first dual GSK3β inhibitor/Nrf2 inducer. A new multitarget therapeutic strategy for Alzheimer’s disease I Gameiro, P Michalska, G Tenti, Á Cores, I Buendia, AI Rojo, ... Scientific reports 7 (1), 45701, 2017 | 71 | 2017 |
| When it comes to an end: oxidative stress crosstalk with protein aggregation and neuroinflammation induce neurodegeneration P Michalska, R León Antioxidants 9 (8), 740, 2020 | 62 | 2020 |
| Pharmacological doses of melatonin impede cognitive decline in tau‐related Alzheimer models, once tauopathy is initiated, by restoring the autophagic flux E Luengo, I Buendia, C Fernández‐Mendívil, P Trigo‐Alonso, P Negredo, ... Journal of Pineal Research 67 (1), e12578, 2019 | 61 | 2019 |
| Inclusion complex of ITH12674 with 2-hydroxypropyl-β-cyclodextrin: Preparation, physical characterization and pharmacological effect P Michalska, A Wojnicz, A Ruiz-Nuño, S Abril, I Buendia, R León Carbohydrate polymers 157, 94-104, 2017 | 60 | 2017 |
| Neuroprotective mechanism of the novel melatonin derivative Neu-P11 in brain ischemia related models I Buendia, V Gómez-Rangel, L González-Lafuente, E Parada, R León, ... Neuropharmacology 99, 187-195, 2015 | 45 | 2015 |
| New melatonin–cinnamate hybrids as multi-target drugs for neurodegenerative diseases: Nrf2-induction, antioxidant effect and neuroprotection I Buendia, E Navarro, P Michalska, I Gameiro, J Egea, S Abril, A López, ... Future medicinal chemistry 7 (15), 1961-1969, 2015 | 42 | 2015 |
| Nrf2 plays a protective role against intravascular hemolysis-mediated acute kidney injury A Rubio-Navarro, C Vázquez-Carballo, M Guerrero-Hue, ... Frontiers in Pharmacology 10, 740, 2019 | 40 | 2019 |
| Antioxidant, anti-inflammatory and neuroprotective profiles of novel 1, 4-dihydropyridine derivatives for the treatment of Alzheimer’s disease P Michalska, P Mayo, C Fernández-Mendívil, G Tenti, P Duarte, I Buendia, ... Antioxidants 9 (8), 650, 2020 | 29 | 2020 |
| MAFG is a potential therapeutic target to restore chemosensitivity in cisplatin-resistant cancer cells by increasing reactive oxygen species O Vera-Puente, C Rodriguez-Antolin, A Salgado-Figueroa, P Michalska, ... Translational Research 200, 1-17, 2018 | 28 | 2018 |
| ITH14001, a CGP37157-nimodipine hybrid designed to regulate calcium homeostasis and oxidative stress, exerts neuroprotection in cerebral ischemia I Buendia, G Tenti, P Michalska, I Méndez-López, E Luengo, M Satriani, ... ACS chemical neuroscience 8 (1), 67-81, 2017 | 26 | 2017 |
| New Nrf2-inducer compound ITH12674 slows the progression of retinitis pigmentosa in the mouse model rd10 L Campello Blasco, O Kutsyr, A Noailles, P Michalska, ... Cellular Physiology & Biochemistry Press, 2020 | 23 | 2020 |
| Novel multitarget hybrid compounds for the treatment of Alzheimer’s disease P Michalska, I Buendia, L Barrio, R Leon Current Topics in Medicinal Chemistry 17 (9), 1027-1043, 2017 | 19 | 2017 |
| Enhanced stability and bioactivity of natural anticancer topoisomerase I inhibitors through cyclodextrin complexation V González-Ruiz, Á Cores, O Martín-Cámara, K Orellana, ... Pharmaceutics 13 (10), 1609, 2021 | 17 | 2021 |
| Bisavenathramide analogues as Nrf2 inductors and neuroprotectors in in vitro models of oxidative stress and hyperphosphorylation Á Cores, S Abril, P Michalska, P Duarte, AI Olives, MA Martín, ... Antioxidants 10 (6), 941, 2021 | 17 | 2021 |
| Tuning melatonin receptor subtype selectivity in oxadiazolone-based analogues: Discovery of QR2 ligands and NRF2 activators with neurogenic properties C Herrera-Arozamena, M Estrada-Valencia, C Pérez, L Lagartera, ... European Journal of Medicinal Chemistry 190, 112090, 2020 | 17 | 2020 |
| Melatonin-sulforaphane hybrid ITH12674 attenuates glial response in vivo by blocking LPS binding to MD2 and receptor oligomerization P Michalska, I Buendia, P Duarte, C FernandezMendivil, P Negredo, ... Pharmacological Research 152, 104597, 2020 | 15 | 2020 |
| Resveratrol-based MTDLs to stimulate defensive and regenerative pathways and block early events in neurodegenerative cascades C Herrera-Arozamena, M Estrada-Valencia, P López-Caballero, C Pérez, ... Journal of Medicinal Chemistry 65 (6), 4727-4751, 2022 | 10 | 2022 |
